Completed PHASE4 INTERVENTIONAL 2-arm NCT01363661

Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris (MEDCOR)

Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention

Sponsor: Therabel Pharma SA/NV

Conditions Atherosclerosis Stable Angina Pectoris

Interventions Coruno Placebo

Updated 6 times since 2017 Last updated: Sep 25, 2014 Started: Jun 30, 2011 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01363661, this PHASE4 trial focuses on Atherosclerosis and Stable Angina Pectoris and remains completed. Sponsored by Therabel Pharma SA/NV, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Therabel Pharma SA/NV

Data source: Therabel Pharma SA/NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aalst, Belgium